An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome

Trial Profile

An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2016

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Behavioural symptoms; Fragile X syndrome
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 11 Apr 2016 Status changed from completed to discontinued because study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212
    • 12 Feb 2015 Status changed from discontinued to completed, as reported by ClinicalTrials.gov.
    • 07 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top